Home  |  Contact

UniProtKB/Swiss-Prot Q9GZX7: Variant p.Trp80Arg

Single-stranded DNA cytosine deaminase
Gene: AICDA
Variant information

Variant position:  80
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Tryptophan (W) to Arginine (R) at position 80 (W80R, p.Trp80Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and aromatic (W) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In HIGM2.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  80
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  198
The length of the canonical sequence.

Location on the sequence:   LFLRYISDWDLDPGRCYRVT  W FTSWSPCYDCARHVADFLRG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRG

                              LFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRG

Mouse                         LFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVAEFLRW

Bovine                        LFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRG

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 198 Single-stranded DNA cytosine deaminase
Domain 23 – 129 CMP/dCMP-type deaminase
Metal binding 87 – 87 Zinc; catalytic
Metal binding 90 – 90 Zinc; catalytic
Beta strand 76 – 84


Literature citations

Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2).
Revy P.; Muto T.; Levy Y.; Geissmann F.; Plebani A.; Sanal O.; Catalan N.; Forveille M.; Dufourcq-Lagelouse R.; Gennery A.; Tezcan I.; Ersoy F.; Kayserili H.; Ugazio A.G.; Brousse N.; Muramatsu M.; Notarangelo L.D.; Kinoshita K.; Honjo T.; Fischer A.; Durandy A.;
Cell 102:565-575(2000)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1); VARIANTS HIGM2 TRP-24; ARG-80; PRO-106; VAL-139 AND SER-151;

Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to activation-induced cytidine deaminase deficiency.
Quartier P.; Bustamante J.; Sanal O.; Plebani A.; Debre M.; Deville A.; Litzman J.; Levy J.; Fermand J.P.; Lane P.; Horneff G.; Aksu G.; Yalcin I.; Davies G.; Tezcan I.; Ersoy F.; Catalan N.; Imai K.; Fischer A.; Durandy A.;
Clin. Immunol. 110:22-29(2004)
Cited for: VARIANTS HIGM2 TRP-24; TYR-56; ARG-80; ARG-87; PRO-106; VAL-139; SER-151 AND SER-174;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.